Trinity Partners, based in Waltham, Mass., released an annual report today that ranked dozens of new drugs approved in 2015 by the U.S. Food and Drug Administration (FDA) based on therapeutic benefits, R&D costs, and commercial sales. And for the second year, Trinity found that orphan disease drugs generally haven’t done all that well at launch and often continued to stumble after three years of sales.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,